| Bispecific antibodies against cd3 and cd20 |
2022-11-06 |
2023-1-01 |
|
| AXL-specific antibody-drug conjugates for cancer treatment |
2022-10-28 |
2022-12-08 |
|
| ANTIBODIES THAT BIND B7H4 |
2022-10-17 |
2022-11-30 |
|
| Antibodies against cd38 for treatment of multiple myeloma |
2022-9-20 |
2022-11-01 |
|
| Antibodies binding axl |
2022-9-19 |
2022-11-01 |
|
| Binding agents binding to pd-l1 and cd137 and use thereof |
2022-8-24 |
2023-3-23 |
|
| Anti-cd38 antibody formulations and uses thereof |
2022-8-09 |
2022-8-19 |
|
| Multispecific antibodies against cd40 and cd137 |
2022-8-03 |
2023-3-23 |
|
| Antibodies for use in therapy |
2022-7-21 |
2022-9-01 |
|
| Multispecific binding agents against cd40 and cd137 in combination therapy for … |
2022-7-13 |
2023-1-19 |
|
| Combination dosage regime of cd137 and pd-l1 binding agents |
2022-6-20 |
2022-12-29 |
|
| Humanized or chimeric CD3 antibodies |
2022-6-03 |
2022-6-23 |
|
| Recombinant monovalent antibodies and methods for production thereof |
2022-5-26 |
2022-12-15 |
|
| PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 … |
2022-5-09 |
2022-11-10 |
|
| Humanized or chimeric cd3 antibodies |
2022-5-09 |
2022-12-08 |
|
| Methods of treating cancer with a combination of an anti-pd-1 antibody and an … |
2022-5-01 |
2022-7-01 |
|
| Methods of treating cancer with a combination of a platinum-based agent and an … |
2022-4-28 |
2022-7-01 |
|
| Multispecific antigen-binding molecule with improved internalization … |
2022-4-06 |
2023-3-09 |
|
| Non-activating antibody variants |
2022-3-11 |
2022-9-15 |
|
| Multispecific binding agents against cd40 and cd137 in therapy |
2022-3-09 |
2022-9-15 |
|
| Heterodimeric antibody FC-containing proteins and methods for production … |
2022-3-08 |
2022-3-31 |
|
| Bispecific antibodies against CD3 and CD20 |
2022-2-10 |
2022-3-03 |
|
| Pharmaceutical compositions comprising bispecific antibodies directed against … |
2022-2-10 |
2022-4-01 |
|
| Agonistic tnf receptor binding agents |
2022-1-28 |
2022-2-17 |
|
| Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic … |
2021-12-22 |
2022-4-14 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-12-22 |
2023-3-21 |
2023-3-21 |
| Modified immunoglobulin with affinity for fcgammariib and method of use thereof |
2021-12-22 |
2022-6-30 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-12-22 |
2023-1-10 |
2023-1-10 |
| Bispecific antibody against cd3 and cd20 in combination therapy for treating … |
2021-12-22 |
2022-4-14 |
|
| Bispecific antibody against cd3 and cd20 in combination therapy for treating … |
2021-12-21 |
2022-4-21 |
|
| Bispecific antibody against cd3 and cd20 in combination therapy for treating … |
2021-12-21 |
2022-4-14 |
|
| Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for … |
2021-12-17 |
2022-1-28 |
|
| Antibodies against human cd38 |
2021-12-14 |
2022-6-30 |
|
| Dosing regimens for anti-tf-antibody drug-conjugates |
2021-12-10 |
2022-8-25 |
|
| Antibody and taxane combination therapy |
2021-12-07 |
2022-10-01 |
|
| Monoclonal antibodies against HER2 |
2021-11-02 |
2021-12-02 |
|
| Human antibodies and antibody-drug conjugates against cd74 |
2021-10-15 |
2022-10-13 |
|
| Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 … |
2021-10-01 |
2022-4-07 |
|
| Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 … |
2021-10-01 |
2022-4-07 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-9-10 |
2023-4-13 |
|
| Bispecific antibody against cd3 and cd20 in combination therapy for treating … |
2021-9-10 |
2023-4-13 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-9-10 |
2023-4-13 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-9-10 |
2023-4-13 |
|
| Bispecific antibody against CD3 and CD20 in combination therapy for treating … |
2021-9-10 |
2023-4-13 |
|
| Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic … |
2021-9-10 |
2023-4-13 |
|
| Antibody therapy |
2021-9-02 |
2022-4-21 |
|
| Human monoclonal antibodies against cd20 for use in the treatment of multiple … |
2021-7-07 |
2021-7-28 |
|
| Anti-tissue factor antibody-drug conjugates and their use in the treatment of … |
2021-6-29 |
2022-5-01 |
|
| Antibodies |
2021-6-21 |
2022-2-17 |
|
| Potency assays for antibody drug substance binding to an fc receptor |
2021-6-16 |
2022-6-09 |
|
| Methods of producing heterodimeric antibodies |
2021-6-15 |
2021-8-31 |
|
| Method for treating cancer |
2021-6-14 |
2022-5-05 |
|
| Antibody formulation |
2021-4-29 |
2021-6-30 |
|
| Methods of treating cancer with a combination of an anti-vegf antibody and an … |
2021-4-26 |
2021-6-30 |
|
| Production of heterodimeric proteins |
2021-4-18 |
2021-6-30 |
|
| Human antibody drug conjugates against tissue factor |
2021-3-10 |
2021-12-23 |
|
| VARIANTS OF ANTI-CD38 ANTIBODIES AND THEIR USES |
2021-2-11 |
2021-3-31 |
|
| Anti-tissue factor antibody-drug conjugates and their use in the treatment of … |
2021-2-03 |
2021-3-25 |
|
| Bispecific antibodies against her2 |
2021-1-14 |
2021-10-21 |
|
| Method for producing a controlled mixture of two or more different antibodies |
2020-12-17 |
2021-1-31 |
|
| Agents, uses and methods for treatment |
2020-12-11 |
2021-9-23 |
|
| Antibody variants having modifications in the constant region |
2020-11-16 |
2021-5-27 |
|
| Agent, uses and methods for treatment |
2020-11-13 |
2021-9-02 |
|
| Agents, uses and methods for the treatment of synucleinopathy |
2020-11-03 |
2021-3-04 |
|
| Axl-specific antibodies for cancer treatment |
2020-10-07 |
2020-11-30 |
|
| Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer |
2020-9-11 |
2021-3-18 |
|
| Monoclonal antibodies against her2 epitope |
2020-8-26 |
2021-4-29 |
|
| Methods of treating cancer with a combination of a platinum-based agent and an … |
2020-8-17 |
2020-10-29 |
|
| Anti-tissue factor antibody-drug conjugates and their use in the treatment of … |
2020-8-17 |
2020-10-29 |
|
| Axl antibody-drug conjugates for use in treating cancer |
2020-7-17 |
2022-5-25 |
|
| STABLE IgG4 ANTIBODIES |
2020-7-15 |
2021-3-04 |
|
| Human monoclonal antibodies against cd25 |
2020-5-26 |
2021-4-15 |
|
| Human antibodies against tissue factor and methods of use thereof |
2020-5-21 |
2021-6-10 |
|
| Anti-tissue factor antibody-drug conjugates and their use in the treatment of … |
2020-4-21 |
2020-6-30 |
|
| Agonistic tnf receptor binding agents |
2020-2-20 |
2020-4-30 |
|
| Inert format |
2020-2-06 |
2020-10-22 |
|
| Heterodimeric antibody fc-containing proteins and methods for production … |
2020-1-30 |
2020-8-20 |
|
| Antibody-drug conjugate lyophilised formulation |
2020-1-14 |
2020-8-06 |
|
| Antibodies against human cd38 |
2020-1-08 |
2020-3-20 |
|
| Monoclonal antibodies against c-Met |
2019-12-19 |
2020-1-16 |
|
| Heterodimeric antibody FC-containing proteins and methods for production … |
2019-12-18 |
2022-6-16 |
2022-6-16 |
| Bispecific antibodies against her2 and cd3 |
2019-10-29 |
2020-8-27 |
|
| Axl-specific antibodies for treatment of non-small cell lung cancer |
2019-9-26 |
2020-4-02 |
|
| Antibodies against pd-l1 |
2019-8-29 |
2019-10-31 |
|
| CD38 ANTIBODY VARIANTS AND THEIR USES |
2019-7-15 |
2022-8-31 |
|
| Trogocytosis-mediated therapy using cd38 antibodies |
2019-7-15 |
2021-5-19 |
|
| Human monoclonal antibodies against CD20 |
2019-7-08 |
2021-7-08 |
2021-7-08 |
| Monoclonal antibodies aganist her2 |
2019-6-02 |
2019-7-31 |
|
| METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A … |
2019-5-07 |
2021-8-04 |
|
| Methods of treating cancer with a combination of an anti-pd-1 antibody and an … |
2019-5-07 |
2022-3-24 |
|
| Methods of treating cancer with a combination of an anti-pd-1 antibody and an … |
2019-5-07 |
2019-11-14 |
|
| Modulation of complement-dependent cytotoxicity through modifications of the c- … |
2019-4-30 |
2020-4-30 |
|
| Heterodimeric antibody fccontaining proteins and methods for production thereof |
2019-4-16 |
2019-6-30 |
|
| PHARMACEUTICAL COMPOSITION, USE OF THE PHARMACEUTICAL COMPOSITION, METHODS FOR … |
2019-2-08 |
2020-12-08 |
|
| Humanized or chimeric cd3 antibodies |
2018-11-20 |
2019-8-23 |
|
| Combination treatment of CD38-expressing tumors |
2018-1-23 |
2018-2-15 |
|
| Antibodies against CD38 for treatment of multiple myeloma |
2018-1-09 |
2018-6-28 |
|
| New dosage regimens for antibody drug conjugates based on anti-axl antibodies |
2017-7-07 |
2018-1-11 |
|